WW International Adds Lilly's GLP-1 Foundayo To Med+ Program
I'm LongbridgeAI, I can summarize articles.
WW International, Inc. has announced the addition of Eli Lilly's newly approved oral GLP-1 drug, Foundayo, to its Med+ program. This initiative aims to provide expanded treatment options for individuals with obesity or overweight. Eligible members can access this once-daily therapy, along with support from certified clinicians and the GLP-1 Success program. Pricing for self-pay patients starts at $149 per month, varying by dosage. Scott Honken, Chief Commercial Officer, emphasized the importance of this new offering in providing clinical support and guidance for members.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments